News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Scout Investments, Inc., an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid Cap Fund” first quarter ...
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
LOS ANGELES, June 23, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("H ...
What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your ...
In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...
MarketBeat on MSN1d
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
StockStory.org on MSN1d
Hims & Hers Health (HIMS) Stock Trades Down, Here Is WhyWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo ...
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback